Gilead Sciences, Inc.

Gregory F Chin

Michael R Mish

Richard L Mackman

Jeff A Zablocki

Hai Yang

Samuel E Metobo

Evangelos Aktoudianakis

Dustin S Siegel

Michael O Clarke

Bindu Goyal

David Sperandio

Hyung-Jung Pyun

Scott D Schroeder

Jinfa Du

Tetsuya Kobayashi

Hon Chung Hui

Robert H Jiang

Britton Kenneth Corkey

Petr Jansa

Ruben Martinez

Kristyna M Elbel

Sophie Shevick

Eda Y Canales

Rick Andrew Lee

Devan Naduthambi

Byoung-Kwon Chun

Mark J Bartlett

Joshua J Van Veldhuizen

Stephen E Ammann

Jason K Perry

Jennifer Leigh Cosman

Manuel Munoz

Weng K Chang

Henok H Kinfe

Deeba Ensan

Christopher J Swank

Jessica L McKinley

Stephen Ho

Xinpei Cai

Kevin X Rodriguez

Scott E Lazerwith

Lianhong Xu

Dmitry Koltun

Eric Q Parkhill

Ryan McFadden

Nathan D Shapiro

Yunfeng Eric Hu

Xiaochun Han

Daniel H Byun

Doris T Tang

Michael O' Neil Hanrahan Clarke

Tim Hansen

Kyle C Tamshen

Tiago Vieira

Pavel R Badalov

Andrea Ambrosi

Beau P Pritchett

Xianghong Wang

Stephen P Lathrop

The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

Sars-cov2 main protease inhibitors

The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido[3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them.

Toll like receptor modulator compounds

The present disclosure provides compounds for treating a variety of diseases, such as respiratory syncytial virus (RSV), HRV, hMPV, Ebola, Zika, West Nile, Dengue, and HCV.

Antiviral compounds

The present disclosure provides pyrimidine dione compounds of Formula I

CD73 compounds

SARS-COV2 main protease inhibitors

The present disclosure describes 4'-fluoromethyl nucleosides for treating viral infections, including Dengue.

Provided herein is A compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the various substituents are described herein.

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them.

The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating cancers.

Imidazopyrimidine derivatives

This application relates generally to toll like receptor modulator compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR8), and methods of making and using them. The toll-like receptor modulators of the present invention include compounds such as 

This application relates to chemical compounds which may act as inhibitors of, or which may otherwise modulate the activity of, a bromodomain-containing protein, including bromodomain-containing protein 4 (BRD4), and to compositions and formulations containing such compounds, and methods of using and making such compounds. Compounds include compounds of Formula (I) wherein R, R, R, R, R, R, R, and Rare described herein.

Benzimidazole derivatives as bromodomain inhibitors

Growing community of inventors

San Francisco, CA, United States of America

Gregory F Chin